Last edition
News about
Lupin Posts 37 percent Q3 Profit Growth on Record US Sales
Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.
Centivax Begins Phase-I Trial of Universal Flu Vaccine
Unlike conventional seasonal influenza vaccines, which must be reformulated annually to attempt to match predicted circulating strains, Centi-Flu 01 is designed to focus both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate, and are shared across strains and distance subtypes.
Syngene Partners with Johns Hopkins University for Early Drug Discovery
The collaboration between Syngene International and John Hopkins University is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research.
Annovis Secures DSMB Nod to Advance Phase-III Buntanetap Trial in Alzheimer's
During the open session, Annovis presented an overview of the trial status, including enrollment progress, adverse events and study timelines. In the closed session, attended exclusively by DSMB voting members to ensure full objectivity and by an unblinded reporting statistician, unmasked safety data were reviewed.
Pharma-to-Wellness Play: USV Secures Controlling Interest in Wellbeing Nutrition
USV has acquired a 79 percent stake in Wellbeing Nutrition, a leading consumer healthcare and nutrition company, in a deal valued at INR 1,583 crore. The acquisition marks a strategic move by USV to strengthen its presence in the fast-growing consumer wellness and nutrition segment.
ASPA - CRISIL Counterfeiting Report to Debut at TAF Connect 2026
The Authentication Solution Providers’ Association (ASPA), in partnership with CRISIL, is set to unveil the State of Counterfeiting in India 2025 report at TAF Connect 2026, a one-day national conference scheduled for March 16, 2026, in Mumbai.
Sanofi Removes CEO Paul Hudson Amid Stalled Turnaround
Sanofi has removed chief executive officer Paul Hudson following a stalled turnaround effort and growing pressure around the performance of its vaccine business, marking a significant leadership shift at the French pharmaceutical major.
Ribo and Madrigal Enter Global Licensing Deal for siRNA Programmes Targeting MASH
Suzhou Ribo Life Science and Madrigal Pharmaceuticals have signed a worldwide licensing agreement covering six pre-clinical siRNA programmes for metabolic dysfunction-associated steatohepatitis, with potential milestone payments of up to USD 4.4 billion.
Iqvia and DCRI have formed a strategic collaboration to enhance the design and execution of obesity and cardiometabolic clinical trials, combining global operational capabilities with academic research expertise.
Galderma Launches First OBT-Based Restylane Injectables in Japan
Galderma has launched Restylane Defyne and Restylane Refyne in Japan, marking the first authorization of hyaluronic acid injectables powered by its proprietary Optimal Balance Technology (OBT) in the country.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy